← Back to Search

Behavioural Intervention

App for Glaucoma Medication Recall

N/A

Waitlist Available

Led By Frank Brodie, MD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with a diagnosis of glaucoma (any type)

Drop regimen of at least 2 pressure-lowering drops

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 month follow up from time of intervention

Awards & highlights

Study Summary

This trial will test if an app can help glaucoma patients remember the eye drops they need & when to take them. Participants will be divided into two groups: those who use the app & those who don't.

Who is the study for?

This trial is for glaucoma patients who manage their condition with at least two pressure-lowering eye drops and can communicate in English, Spanish, or Cantonese. It's not suitable for those who can't use eye drops by themselves or have trouble interacting with an app due to visual or other barriers.Check my eligibility

What is being tested?

The study tests if a special instructional app helps people remember how and when to take their glaucoma eye drops better than without the app. Participants will be split into two groups: one using the app and one not, then checked after a month on how well they recall their drop schedule.See study design

What are the potential side effects?

Since this trial involves an educational app rather than medication, there are no direct medical side effects expected from participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with glaucoma.

Select...

I use at least 2 types of eye drops to lower eye pressure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 month follow up from time of intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 month follow up from time of intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month follow up from time of intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage accuracy of drop regimen recall

Secondary outcome measures

Overall medication adherence, assessed through the modified Morisky Adherence Scale, a widely published scale for general medication adherence

Side effects data

From 2017 Phase 4 trial • 134 Patients • NCT02858713

12%

Skin manifestations

various musculoskelatal disorders

Lung and skin infections

Elevated creatinin levels

relapse of carcinoma in situ of the glottis

Nausea

Elevated liver enzymes

Infection in knee prosthesis

100%

80%

60%

40%

20%

Study treatment Arm

App as Intervention + Enstilar©

Conventional Instructions + App as Intervention + Enstilar©

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: App armExperimental Treatment1 Intervention

The intervention is an in-office app that contains graphical and narrated information on a patient's specific drop regimen, and includes a quiz and a graphical print-out of their drop schedule. The patient will use the app during their clinic visit.

Group II: Standard armActive Control1 Intervention

The standard arm will be the standard of care, which involves a provider explanation of their drop regimen (using a phone interpreter if needed).

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor

2,505 Previous Clinical Trials

15,237,475 Total Patients Enrolled

8 Trials studying Glaucoma

76,711 Patients Enrolled for Glaucoma

Frank Brodie, MDPrincipal InvestigatorUCSF, Department of Ophthalmology

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for participating in this medical experiment?

"This investigation, which was first made available on October 1st 2023 is no longer in the process of recruiting. The information provided on clinicaltrials.gov has been last updated on September 13th 2023. At present time, 182 other studies are actively enrolling patients into their trials."

Answered by AI

Recent research and studies

Medical CareJournal

Physician Communication and Patient Adherence to Treatment

Haskard Zolnierek, Kelly B., and M Robin DiMatteo. 2009. “Physician Communication and Patient Adherence to Treatment”. Medical Care. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/mlr.0b013e31819a5acc.

OphthalmologyJournal

The Most Common Barriers to Glaucoma Medication Adherence

Newman-Casey, Paula Anne, Alan L. Robin, Taylor Blachley, Karen Farris, Michele Heisler, Ken Resnicow, and Paul P. Lee. 2015. “The Most Common Barriers to Glaucoma Medication Adherence”. Ophthalmology. Elsevier BV. doi:10.1016/j.ophtha.2015.03.026.

clinicaltrials.govStudy

An App-based Instructional Platform to Improve Eye Drop Recall

2024. "An App-based Instructional Platform to Improve Eye Drop Recall". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06045390.

All > Glaucoma